[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2011011716A - Derivados de isoquinolina novedosos. - Google Patents

Derivados de isoquinolina novedosos.

Info

Publication number
MX2011011716A
MX2011011716A MX2011011716A MX2011011716A MX2011011716A MX 2011011716 A MX2011011716 A MX 2011011716A MX 2011011716 A MX2011011716 A MX 2011011716A MX 2011011716 A MX2011011716 A MX 2011011716A MX 2011011716 A MX2011011716 A MX 2011011716A
Authority
MX
Mexico
Prior art keywords
isoquinoline derivatives
novel isoquinoline
novel
derivatives
compound
Prior art date
Application number
MX2011011716A
Other languages
English (en)
Inventor
Li Chen
Lichun Feng
Yongguo Li
Guolong Wu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2011011716A publication Critical patent/MX2011011716A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a un compuesto de la fórmula (I) o una sal del mismo farmacéuticamente aceptable, en donde R1 a R7 tienen el significado dado en la reivindicación 1, que puede ser utilizado en la forma de una composición farmacéutica.
MX2011011716A 2009-05-08 2010-05-05 Derivados de isoquinolina novedosos. MX2011011716A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2009071693 2009-05-08
PCT/EP2010/056062 WO2010128061A1 (en) 2009-05-08 2010-05-05 Novel isoquinoline derivatives

Publications (1)

Publication Number Publication Date
MX2011011716A true MX2011011716A (es) 2012-01-03

Family

ID=42272377

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011716A MX2011011716A (es) 2009-05-08 2010-05-05 Derivados de isoquinolina novedosos.

Country Status (13)

Country Link
US (1) US8258149B2 (es)
EP (1) EP2427460B1 (es)
JP (1) JP2012526077A (es)
KR (1) KR20120007549A (es)
CN (1) CN102421774A (es)
AU (1) AU2010244473A1 (es)
BR (1) BRPI1014684A2 (es)
CA (1) CA2760339A1 (es)
ES (1) ES2462498T3 (es)
IL (1) IL216062A0 (es)
MX (1) MX2011011716A (es)
SG (1) SG175926A1 (es)
WO (1) WO2010128061A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102796096B (zh) * 2011-05-27 2016-09-14 中国科学院上海药物研究所 六氢二苯并[a,g]喹嗪类化合物、其制备方法、药物组合物及其应用
US9181237B2 (en) 2013-10-04 2015-11-10 Mallinckrodt Llc Substituted berbines and their synthesis
WO2015102380A1 (ko) * 2013-12-31 2015-07-09 한국화학연구원 신규한 8-옥소프로토베르베린 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 nfat5의 활성 관련 질환의 예방 또는 치료용 약학적 조성물
US9650389B2 (en) * 2013-12-31 2017-05-16 Korea Research Institute Of Chemical Technology 8-oxoprotoberberine derivative or pharmaceutically acceptable salt thereof, preparation method therefor and pharmaceutical composition for preventing or treating diseases associated with activity of NFAT5, containing same as active ingredient
KR20250004957A (ko) * 2022-03-16 2025-01-08 상하이 시지앙 바이오테크널러지 컴퍼니 리미티드 질소 함유 헤테로고리계 화합물
KR20250064975A (ko) * 2023-11-03 2025-05-12 동아대학교 산학협력단 이소퀴놀린 유도체를 유효성분으로 포함하는 치매의 예방 또는 치료용 약학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000021073A (ko) * 1998-09-25 2000-04-15 박원배 콜레스테롤 생합성 저해제
CA2510337C (en) * 2002-11-12 2013-01-08 Rutgers, The State University Of New Jersey Topoisomerase-targeting agents
CN1759834B (zh) * 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
CN101153039B (zh) 2006-09-30 2010-12-01 中国科学院上海药物研究所 13，13a-二氢小檗碱衍生物及其药物组合物和用途
CN100494193C (zh) * 2006-12-14 2009-06-03 西南大学 8-辛基小檗碱盐酸盐、合成方法及应用
CN101104618B (zh) * 2007-05-25 2010-05-26 西南大学 长链烷基小檗碱盐衍生物、合成方法及用途
US8003795B2 (en) * 2007-06-22 2011-08-23 Cvi Pharmaceuticals Limited Compounds and compositions for reducing lipid levels
EP2014651A1 (en) 2007-07-12 2009-01-14 Exonhit Therapeutics SA Compounds and methods for modulating Rho GTPases

Also Published As

Publication number Publication date
EP2427460A1 (en) 2012-03-14
EP2427460B1 (en) 2014-03-26
WO2010128061A1 (en) 2010-11-11
JP2012526077A (ja) 2012-10-25
CA2760339A1 (en) 2010-11-11
US8258149B2 (en) 2012-09-04
CN102421774A (zh) 2012-04-18
BRPI1014684A2 (pt) 2016-04-12
US20100286396A1 (en) 2010-11-11
KR20120007549A (ko) 2012-01-20
SG175926A1 (en) 2011-12-29
AU2010244473A1 (en) 2011-12-15
IL216062A0 (en) 2012-01-31
ES2462498T3 (es) 2014-05-23

Similar Documents

Publication Publication Date Title
IN2012DN03337A (es)
MY138941A (en) Aryl-pyridine derivatives
IN2012DN00765A (es)
MX2010005824A (es) Derivados de aminotiazol.
TW200738241A (en) Pyridazine derivatives
MX2012000414A (es) Derivados piridin-4-ilo.
MY162940A (en) Quinoline derivative-containing pharmaceutical composition
MX2022007264A (es) Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas.
MX2009003939A (es) Derivados de imidazolona e imidazolidinona como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 para diabetes.
SG2012079653A (en) Tropane compounds
MY165918A (en) Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof
MX2011008176A (es) Derivados de 3,3'-espiroindolinona como agentes anticancerigenos.
MX338551B (es) Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa.
TW200740764A (en) Pyrazolone derivatives
IN2012DN01232A (es)
MY183039A (en) Pyridin-2-yl derivatives as immunomodulating agents
PH12015502429A1 (en) Dicarboxylic acid compound
MX2010005714A (es) Compuestos de piridina.
MX2011011716A (es) Derivados de isoquinolina novedosos.
TW200616976A (en) Pyrimidine derivatives
PH12012500992A1 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
JO2781B1 (en) A new process for the synthesis of ivabradine and its addition salts with pharmaceutically acceptable acid.
MX2013008256A (es) Derivados novedosos de tetrahidroquinolina.
MX2013002694A (es) Derivados de tetrahidroquinolina usados como activadores de proteina cinasa activada por monofosfato de adenosina.
MX2009010225A (es) Nuevos compuestos 707 y sus usos.

Legal Events

Date Code Title Description
FG Grant or registration